Interventional Cardiology at a Pivot Point

References

• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20. doi:10.1016/S0140-6736(03)12113-7
   PubMed Web of Science ®Google Scholar
• Fox KAA, Clayton TC, Damman P, et al.; for the FIR Collaboration. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST segment elevation acute coronary syndrome, a meta-analysis of individual patient data. Am Coll Cardiol. 2010;55:2435–2445. doi:10.1016/j.jacc.2010.03.007
   PubMed Web of Science ®Google Scholar
• Boden WE, O’Rourke RA, Treo KK, et al.; for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516. doi:10.1056/NEJMoa070829
   PubMed Web of Science ®Google Scholar
• Al-Lamme R, Thompson D, Dehbi HM, et al.; ORBITA Investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet. 2018;391:31–40. doi:10.1016/S0140-6736(17)32714-9
   Google Scholar
• Patel MR, Person ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;363:498. doi:10.1056/NEJMx100044
   Google Scholar
• Lee BK, Lim HS, Fearon WF, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131:1054–1060. doi:10.1161/CIRCULATIONAHA.114.012636
   Web of Science ®Google Scholar
• Camici PG, Rimoldi OE. Coronary stenosis and transmural perfusion across the left ventricular wall. Eur Heart J. 2014;35:2058–2059. doi:10.1093/eurheartj/ehu206
   Web of Science ®Google Scholar
• Ong P, Camici PG, Beltrame JF, et al.; on behalf on Coronary Vasomotion Disorders International Study Group (COVADIS). International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;205:16–20. doi:10.1016/j.ijcard.2017.08.068
   Web of Science ®Google Scholar
• Abo-Salem E, Chaitman B, Helmy T, Boakye EA, Alkhawam H, Lim M. Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials. J Neurol. 2018;265:578–585. doi:10.1007/s00415-018-8750-x
   Web of Science ®Google Scholar
• D’Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE population cohort study. Eur Heart J. 2016;37:3515–3522. doi:10.1093/eurheartj/ehw229
   PubMed Web of Science ®Google Scholar
• Lung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26:2714–2720. doi:10.1093/eurheartj/ehi471
   Web of Science ®Google Scholar
• Bach DS, Awais M, Gurm HS, Kohnstamm S. Failure of guideline adherence for intervention in patients with severe mitral regurgitation. J Am Coll Cardiol. 2009;54:860–865. doi:10.1016/j.jacc.2009.03.079
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack MJ, et al.; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–1620. doi:10.1056/NEJMoa1514616
   PubMed Web of Science ®Google Scholar
• Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–409. doi:10.1016/j.jacc.2003.09.036
   PubMed Web of Science ®Google Scholar
• Rodes-Cabau J, Hahn RT, Latib A, et al. Transcatheter therapies for treating tricuspid regurgitation. J Am Coll Cardiol. 2016;67:1829–1845. doi:10.1016/j.jacc.2016.01.063
   PubMed Web of Science ®Google Scholar
• Reddy VY, Doshi SK, Kar S, et al.; PREVAIL and PROTECT AF Investigators. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964–2975. doi:10.1016/j.jacc.2017.10.021
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, et al.; on behalf of the SPYRALHTN-OFF MED trial Investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYALHTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–2170. doi:10.1016/S0140-6736(17)32281-X
   PubMed Web of Science ®Google Scholar
• Mauri L, Kario K, Basile J, et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115–129. doi:10.1016/j.ahj.2017.09.006
   PubMed Web of Science ®Google Scholar
• Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5:748–755. doi:10.1161/CIRCINTERVENTIONS.112.971077
   PubMed Web of Science ®Google Scholar
• Kaye DM, HasenfuB G, Neuzil P, et al. One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9(12). Pii: e003662. doi:10.1161/CIRCHEARTFAILURE.116.003662
   Web of Science ®Google Scholar
• HasenfuB G, Hayward C, Burkhoff D, et al.; REDUCE LAP-HF Study Investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicenter, open-label, single-arm, Phase 1 trial. Lancet. 2016;387:1298–1304. doi:10.1016/S0140-6736(16)00704-2
   Web of Science ®Google Scholar